

Revision date: 29-Nov-2012

Version: 2.0

Page 1 of 6

# 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

# Material Name: Salbutamol Inhalation Solution

Trade Name:	Salbutamol
Synonyms:	Albuterol Sulfate
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as bronchodilator

# 2. HAZARDS IDENTIFICATION

Appearance:	Clear, colorless solution
Statement of Hazard:	Non-hazardous in accordance with international standards for workplace safety.
Additional Hazard Information: Short Term: Long Term: Known Clinical Effects:	Not acutely toxic (based on animal data). Animal studies have shown a potential to cause adverse effects on the fetus. Adverse effects associated with therapeutic use include nervousness, headache, increased heart rate (tachycardia).
EU Classification EU Indication of danger:	Not classified

Australian Hazard Classification (NOHSC):	Non-Hazardous Substance. Non-Dangerous Goods.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous				
Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Salbutamol Sulfate	51022-70-9	256-916-8	Repr.Cat3;R63	0-1
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	0-1

Ingredient	CAS Number	EU EINECS/ELINCS List	<b>EU Classification</b>	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*

**Additional Information:** 

\* Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

#### For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES	
Eye Contact:	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Skin Contact:	Wash exposed area with soap and water, remove contaminated clothing and obtain medical assistance if irritation occurs.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

# **5. FIRE FIGHTING MEASURES**

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Material Name: Salbutamol Inhalation Solution Revision date: 29-Nov-2012

Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE	
General Handling:	Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
Storage Conditions:	Store as directed by product packaging.

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

SODIUM CHLORIDE Latvia OEL - TWA Lithuania OEL - TWA	5 mg/m³ 5 mg/m³
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.
Environmental Exposure Controls:	Refer to specific Member State legislation for requirements under Community environmental legislation.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Colorless
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Water Solubility:	Aqueous solution		

# **10. STABILITY AND REACTIVITY**

Chemical Stability: Conditions to Avoid: Incompatible Materials: Stable under normal conditions of use. Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from strong oxidizers

Material Name: Salbutamol Inhalation Solution Revision date: 29-Nov-2012

11. TOXICOLOGICAL INFORMATION

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### Salbutamol Sulfate

Rat Oral LD50 > 2500 mg/kg Rat Para-periosteal LD50 59.1 mg/kg Rat Intraperitoneal LD50 295 mg/kg Mouse Oral LD50 1950 mg/kg Mouse Intravenous LD50 48.7 mg/kg

#### SODIUM CHLORIDE

RatSub-tenon injection (eye)LC50/1hr> 42 g/m3RatOralLD 503 g/kgMouseOralLD 504 g/kgRabbitDermalLD 50> 10 g/kgAcute Toxicity Comments:A greater than symbolAcute the bisheat deeper

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

#### SODIUM CHLORIDE

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### Salbutamol Sulfate

**Reproductive & Fertility** 50 mg/kg No effects at maximum dose Rat Oral NOAEL Embryo / Fetal Development LOAEL Mouse Subcutaneous 0.25 mg/kg Teratogenic Embryo / Fetal Development Rabbit 50 mg/kg/day Teratogenic Oral LOAEL

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Salbutamol Sulfate

Bacterial Mutagenicity (Ames)Salmonella , E. coliNegativeIn Vivo MicronucleusMouseNegativeIn Vitro Chromosome AberrationHuman LymphocytesNegativeMitotic Gene ConversionFungiNegative

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Salbutamol Sulfate

18 Month(s)MouseOral500 mg/kg/dayNOAELNot carcinogenic22 Month(s)HamsterOral50 mg/kg/dayNOAELNot carcinogenic2 Year(s)RatOral2 mg/kg/dayLOAELBenign tumors, Female reproductive system

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

#### Material Name: Salbutamol Inhalation Solution Revision date: 29-Nov-2012

Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDER	ATIONS
Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### **14. TRANSPORT INFORMATION**

#### The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# **15. REGULATORY INFORMATION**

EU Indication of danger: Not classified

#### **OSHA Label:** Non-hazardous in accordance with international standards for workplace safety.

#### **Canada - WHMIS: Classifications**

WHMIS hazard class: D2a\_very toxic materials



Salbutamol Sulfate Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons: EU EINECS/ELINCS List

Present 4

256-916-8

### SODIUM CHLORIDE

Material Name: Salbutamol Inhalation Solution Revision date: 29-Nov-2012

15. REGULATORY INFORMATION		
Inventory - United States TSCA - Sect. 8(b)	Present	
Australia (AICS):	Present	
EU EINECS/ELINCS List	231-598-3	
Vater for Injection		
Inventory - United States TSCA - Sect. 8(b)	Present	
Australia (AICS):	Present	
REACH - Annex IV - Exemptions from the obligations of Register:	Present	
EU EINECS/ELINCS List	231-791-2	

# **16. OTHER INFORMATION**

#### Text of R phrases mentioned in Section 3

R63 - Possible risk of harm to the unbor	n child.
Data Sources:	The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Prepared by:	Product Stewardship Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

### End of Safety Data Sheet